Successes, failures, and future prospects of prodrugs and their clinical impact

References

• Karaman R. Prodrugs design: a new era. New York, USA: Nova Science Publishers, Incorporated; 2014.
   Google Scholar
• Das N, Dhanawat M, Dash B, et al. Codrug: an efficient approach for drug optimization. Eur J Pharm Sci. 2010 Dec 23;41(5):571–588. PubMed PMID: 20888411; eng.
   PubMed Web of Science ®Google Scholar
• Karaman R. Using predrugs to optimize drug candidates. Expert Opin Drug Discov. 2014 Dec 01;9(12):1405–1419.
   PubMed Web of Science ®Google Scholar
• Zeiadeh I, Najjar A, Karaman R. Strategies for enhancing the permeation of CNS-active drugs through the blood-brain barrier: a review. Molecules. 2018 May 28;23(6):1289. PubMed PMID: 29843371.
   PubMed Web of Science ®Google Scholar
• Sinokrot H, Smerat T, Najjar A, et al. Advanced prodrug strategies in nucleoside and non-nucleoside antiviral agents: a review of the recent five years. Molecules. 2017 Oct 16;22(10):1736. PubMed PMID: 29035325.
   PubMed Web of Science ®Google Scholar
• Najjar A, Rajabi N, Karaman R. Recent approaches to platinum(IV) prodrugs: a variety of strategies for enhanced delivery and efficacy. Curr Pharm Des. 2017;23(16):2366–2376. PubMed PMID: 28155621; eng.
   PubMed Web of Science ®Google Scholar
• Karaman R. Prodrugs-current and future drug development strategy. Drug Discovery. 2014;1:11.
   Google Scholar
• Albert A. Chemical aspects of selective toxicity. Nature. 1958 Aug 16;182(4633):421–422. PubMed PMID: 13577867; eng.
   PubMed Web of Science ®Google Scholar
• Sandros MG, Sarraf CB, Tabrizian M. Prodrugs in cardiovascular therapy. Molecules. 2008 May 14;13(5):1156–1178. PubMed PMID: 18560335.
   PubMed Web of Science ®Google Scholar
• Armstrong C. Joint National C. JNC8 guidelines for the management of hypertension in adults. Am Fam Physician. 2014 Oct 1;90(7):503–504. PubMed PMID: 25369633; eng.
   PubMed Web of Science ®Google Scholar
• Gilstrap LG, Fonarow GC, Desai AS, et al. Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction. J Am Heart Assoc. 2017 Feb 11;6(2):e004675. PubMed PMID: 28189999; PubMed Central PMCID: PMC5523765.
   PubMed Web of Science ®Google Scholar
• Sleight P. The HOPE study (Heart outcomes prevention evaluation). J Renin Angiotensin Aldosterone Sys. 2000 Mar;1(1):18–20. PubMed PMID: 11967789; eng.
   PubMedGoogle Scholar
• Vegter S, Nguyen NH, Visser ST, et al. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care. 2011 Sep;17(9):609–616. PubMed PMID: 21902446; eng.
   PubMed Web of Science ®Google Scholar
• Hjermitslev M, Grimm DG, Wehland M, et al. Azilsartan medoxomil, an angiotensin II receptor antagonist for the treatment of Hypertension. Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):225–233. PubMed PMID: 28444983.
   PubMed Web of Science ®Google Scholar
• Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens. 2000 Jan;13(1 Pt 2):18S–24S. PubMed PMID: 10678284; eng.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang X, Nguyen J, et al. Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation. Drug Metab Dispos. 2016 Apr;44(4):554–559. PubMed PMID: 26817948; PubMed Central PMCID: PMC4810765. eng.
   PubMed Web of Science ®Google Scholar
• Sacubitril/valsartan (entresto) for heart failure. JAMA. 2015 Aug 18;314(7):722–723. PubMed PMID: 26284725; eng.
   PubMed Web of Science ®Google Scholar
• Svensson E, Nielsen RB, Hasvold P, et al. Statin prescription patterns, adherence, and attainment of cholesterol treatment goals in routine clinical care: a Danish population-based study. Clin Epidemiol. 2015 Feb 26;7:213–223. PubMed PMID: 25759601; PubMed Central PMCID: PMC4345937.
   PubMed Web of Science ®Google Scholar
• Arnold SV, Kosiborod M, Tang F, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation. 2014 Mar 25;129(12):1303–1309. PubMed PMID: 24496318; PubMed Central PMCID: PMC4103689.
   PubMed Web of Science ®Google Scholar
• Toth PP, Patti AM, Giglio RV, et al. Management of statin intolerance in 2018: still more questions than answers. Am J Cardiovasc Drugs. 2018 Jun;18(3):157–173. PubMed PMID: 29318532; PubMed Central PMCID: PMC5960491.
   PubMed Web of Science ®Google Scholar
• Alagona P Jr. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc Health Risk Manag. 2010 May 25;6:351–362. PubMed PMID: 20531954; PubMed Central PMCID: PMC2879297. eng.
   PubMedGoogle Scholar
• Dorsam RT, Murugappan S, Ding Z, et al. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Hematology. 2003 Dec;8(6):359–365. PubMed PMID: 14668029; eng.
   PubMedGoogle Scholar
• Spartalis M, Tzatzaki E, Spartalis E, et al. The role of prasugrel in the management of acute coronary syndromes: a systematic review. Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4733–4743. PubMed PMID: 29131238; eng.
   PubMed Web of Science ®Google Scholar
• Jiang XL, Samant S, Lesko LJ, et al. Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147–166. PubMed PMID: 25559342; PubMed Central PMCID: PMC5677184. eng.
   PubMed Web of Science ®Google Scholar
• Pirmohamed M. Warfarin: the end or the end of one size fits all therapy? J Pers Med. 2018 Jun 28;8(3):22. PubMed PMID: 29958440; eng.
   PubMed Web of Science ®Google Scholar
• Chen C. Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil. Eur J Clin Pharmacol. 2013 Oct;69(10):1809–1817. PubMed PMID: 23743781; eng.
   PubMed Web of Science ®Google Scholar
• Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs. 2012 Feb 1;26(2):155–183. PubMed PMID: 22296317; eng.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Drugs. 2012 Jan 1;72(1):133–162. PubMed PMID: 22191800; eng.
   PubMed Web of Science ®Google Scholar
• Rohde M, Hakansson AE, Jensen KG, et al. Biological conversion of aripiprazole lauroxil - an N-acyloxymethyl aripiprazole prodrug. Results Pharma Sci. 2014;4:19–25. PubMed PMID: 25756003; PubMed Central PMCID: PMC4050360.
   PubMedGoogle Scholar
• Frampton JE. Aripiprazole lauroxil: a review in schizophrenia. Drugs. 2017 Dec;77(18):2049–2056. PubMed PMID: 29177572; eng.
   PubMed Web of Science ®Google Scholar
• Pliszka S. Issues AWGoQ. practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894–921. PubMed PMID: 17581453.
   PubMed Web of Science ®Google Scholar
• Steer C, Froelich J, Soutullo CA, et al. Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder. CNS Drugs. 2012 Aug 1;26(8):691–705. PubMed PMID: 22762726; eng.
   PubMed Web of Science ®Google Scholar
• Peppercorn MA. Sulfasalazine. Ann Intern Med. 1984;101(3):377.
   PubMed Web of Science ®Google Scholar
• Tursi A. Balsalazide in treating colonic diseases. Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1555–1563. PubMed PMID: 19708827; eng.
   PubMed Web of Science ®Google Scholar
• Wadworth AN, Fitton A. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991 Apr;41(4):647–664. PubMed PMID: 1711964; eng.
   PubMed Web of Science ®Google Scholar
• Prum BE Jr., Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern((R)) guidelines. Ophthalmology. 2016 Jan;123(1):P41–P111. PubMed PMID: 26581556.
   PubMed Web of Science ®Google Scholar
• Linden C, Alm A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging. 1999 May;14(5):387–398. PubMed PMID: 10408738; eng.
   PubMed Web of Science ®Google Scholar
• Teschner S, Burst V. Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy. 2010 Sep;2(5):637–650. PubMed PMID: 20874647; eng.
   PubMed Web of Science ®Google Scholar
• Baluom M, Grossbard EB, Mant T, et al. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. Br J Clin Pharmacol. 2013 Jul;76(1):78–88. PubMed PMID: 23190017; PubMed Central PMCID: PMC3703230. eng.
   PubMed Web of Science ®Google Scholar
• Sweeny DJ, Li W, Clough J, et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos. 2010 Jul;38(7):1166–1176. PubMed PMID: 20371637; eng.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opin Pharmacother. 2016 Dec;17(18):2487–2498. PubMed PMID: 27817224; eng.
   PubMed Web of Science ®Google Scholar
• Colon-Gonzalez F, Kraft WK. Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1277–1286. PubMed PMID: 20795794; PubMed Central PMCID: PMC3155701.
   PubMed Web of Science ®Google Scholar
• Najjar A, Karaman R. The prodrug approach in the era of drug design. Expert Opin Drug Deliv. 2019;16(1):1–5.
   Web of Science ®Google Scholar
• Salvini M, Troia R, Giudice D, et al. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. Expert Opin Drug Metab Toxicol. 2018 Jan 02;14(1):91–99.
   PubMed Web of Science ®Google Scholar
• Smith JP, Weller S, Johnson B, et al. Pharmacokinetics of acyclovir and its metabolites in cerebrospinal fluid and systemic circulation after administration of high-dose valacyclovir in subjects with normal and impaired renal function. Antimicrob Agents Chemother. 2010 Mar;54(3):1146–1151. PubMed PMID: 20038622; PubMed Central PMCID: PMC2825963.
   PubMed Web of Science ®Google Scholar
• MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother. 2004 Jun;53(6):899–901. PubMed PMID: 15140857; eng.
   PubMed Web of Science ®Google Scholar
• Al-Badr AA, Ajarim TDS. Ganciclovir. Profiles Drug Subst Excip Relat Methodol. 2018;43:1–208. PubMed PMID: 29678260; eng.
   PubMedGoogle Scholar
• Mareri A, Lasorella S, Iapadre G, et al. Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects. J Matern Fetal Neonatal Med. 2016;29(10):1657–1664. PubMed PMID: 26135794; eng.
   PubMed Web of Science ®Google Scholar
• Cocohoba JM, McNicholl IR. Valganciclovir: an advance in cytomegalovirus therapeutics. Ann Pharmacother. 2002 Jun;36(6):1075–1079. PubMed PMID: 12022911; eng.
   PubMed Web of Science ®Google Scholar
• Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010 Apr;65(Suppl 2):ii5–ii10. PubMed PMID: 20215135; PubMed Central PMCID: PMC2835511. eng.
   PubMed Web of Science ®Google Scholar
• Sun DQ, Wang HS, Ni MY, et al. Pharmacokinetics, safety and tolerance of single- and multiple-dose adefovir dipivoxil in healthy Chinese subjects. Br J Clin Pharmacol. 2007 Jan;63(1):15–23. PubMed PMID: 16869815; PubMed Central PMCID: PMC2000720.
   PubMed Web of Science ®Google Scholar
• Pockros PJ. Interferon-free hepatitis C therapy: how close are we? Drugs. 2012 Oct 1;72(14):1825–1831. PubMed PMID: 22934796; eng.
   PubMed Web of Science ®Google Scholar
• Keating GM. Sofosbuvir: a review of its use in patients with chronic hepatitis C. Drugs. 2014 Jul;74(10):1127–1146. PubMed PMID: 24958336; eng.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013 May 16;368(20):1878–1887. PubMed PMID: 23607594; eng.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013 Jun 15;381(9883):2100–2107. PubMed PMID: 23499440; eng.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetics of bacampicillin tablets in adults. Bull N Y Acad Med. 1983 Jun;59(5):457–467. PubMed PMID: 6349732; PubMed Central PMCID: PMC1911655. eng.
   PubMedGoogle Scholar
• Sjovall J, Magni L, Bergan T. Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin. Antimicrob Agents Chemother. 1978 Jan;13(1):90–96. PubMed PMID: 626496; PubMed Central PMCID: PMC352190. eng.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Scott Daniels J. Chapter 3 Carboxylic Acids and their Bioisosteres. In: Smith DA, editor. Metabolism, pharmacokinetics and toxicity of functional groups: impact of chemical building blocks on ADMET. Cambridge, UK: The Royal Society of Chemistry; 2010. p. 99–167.
   Google Scholar
• Utsui Y, Inoue M, Mitsuhashi S. In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Jul;31(7):1085–1092. PubMed PMID: 3310868; PubMed Central PMCID: PMC174876.
   PubMed Web of Science ®Google Scholar
• Kakumanu VK, Arora V, Bansal AK. Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil. Int J Pharm. 2006 Jul 24;317(2):155–160. PubMed PMID: 16621365; eng.
   PubMedGoogle Scholar
• Hall RG 2nd, Smith WJ, Putnam WC, et al. An evaluation of tedizolid for the treatment of MRSA infections. Expert Opin Pharmacother. 2018 Sep;19(13):1489–1494. PubMed PMID: 30200779; eng.
   PubMed Web of Science ®Google Scholar
• Lamp KC, Freeman CD, Klutman NE, et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999 May;36(5):353–373. PubMed PMID: 10384859; eng.
   PubMed Web of Science ®Google Scholar
• McBride D, Krekel T, Hsueh K, et al. Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections. Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):331–337. PubMed PMID: 28140693; eng.
   PubMed Web of Science ®Google Scholar
• Denis J, Ledoux MP, Nivoix Y, et al. Isavuconazole: A new broad-spectrum azole. Part 1: in vitro activity. Journal De Mycologie Medicale. 2018 Mar;28(1):8–14. PubMed PMID: 29534853; eng.
   PubMed Web of Science ®Google Scholar
• Ledoux MP, Denis J, Nivoix Y, et al. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity. Journal De Mycologie Medicale. 2018 Mar;28(1):15–22. PubMed PMID: 29551442; eng.
   PubMed Web of Science ®Google Scholar
• Game X, Peyronnet B, Cornu JN. Fesoterodine: pharmacological properties and clinical implications. Eur J Pharmacol. 2018 Aug 15;833:155–157. PubMed PMID: 29803689; eng.
   PubMed Web of Science ®Google Scholar
• Amabile CM, Spencer AP. Parecoxib for parenteral analgesia in postsurgical patients. Ann Pharmacother. 2004 May;38(5):882–886. PubMed PMID: 15039473; eng.
   PubMed Web of Science ®Google Scholar
• Gandey A. FDA rejects parecoxib, only injectible COX-2 inhibitor Medscape2005. Available from: https://www.medscape.com/viewarticle/538344
   Google Scholar
• Hedner T, Samulesson O, Wahrborg P, et al. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs. 2004;64(20):2315–2343. discussion 2344-5. PubMed PMID: 15456329; eng.
   PubMedGoogle Scholar
• Brunell D, Sagher D, Kesaraju S, et al. Studies on the metabolism and biological activity of the epimers of sulindac. Drug Metab Dispos. 2011 Jun;39(6):1014–1021. PubMed PMID: 21383205; PubMed Central PMCID: PMC3100905.
   PubMed Web of Science ®Google Scholar
• Elbini Dhouib I, Jallouli M, Annabi A, et al. A minireview on N-acetylcysteine: an old drug with new approaches. Life Sci. 2016 Apr 15;151:359–363. PubMed PMID: 26946308.
   PubMed Web of Science ®Google Scholar
• Smith JT, Hamilton-Miller JM. Hetacillin: a chemical and biological comparison with ampicillin. Chemotherapy. 1970;15(6):366–378. PubMed PMID: 5514976.
   PubMed Web of Science ®Google Scholar
• Lu HR, Hermans AN, Gallacher DJ. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? Br J Pharmacol. 2012 Jun;166(4):1490–1502. PubMed PMID: 22300168; PubMed Central PMCID: PMC3417462. eng.
   PubMed Web of Science ®Google Scholar
• Southworth H. Predicting potential liver toxicity from phase 2 data: a case study with ximelagatran. Stat Med. 2014 Jul 30;33(17):2914–2923. PubMed PMID: 24623062.
   PubMed Web of Science ®Google Scholar
• Janssen PA, Niemegeers CJ, Schellekens KH, et al. Bezitramide (R 4845), a new potent and orally long-acting analgesic compound. Arzneimittel-Forschung. 1971 Jun;21(6):862–867. PubMed PMID: 5109278; eng.
   PubMedGoogle Scholar
• Yun J, Chung E, Choi KH, et al. Cardiovascular safety pharmacology of sibutramine. Biomol Ther (Seoul). 2015 Jul;23(4):386–389. PubMed PMID: 26157557; PubMed Central PMCID: PMC4489835. eng.
   PubMed Web of Science ®Google Scholar
• Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs. 2007 Jun;16(6):855–866. PubMed PMID: 17501697; eng.
   PubMed Web of Science ®Google Scholar
• Chawla SP, Chua VS, Hendifar AF, et al. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer. 2015 Feb 15;121(4):570–579. PubMed PMID: 25312684; eng.
   PubMed Web of Science ®Google Scholar
• Chawla SP, Papai Z, Mukhametshina G, et al. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial. JAMA Oncol. 2015 Dec;1(9):1272–1280. PubMed PMID: 26378637; eng.
   PubMed Web of Science ®Google Scholar
• Chawla SP, Ganjoo KN, Schuetze S, et al. Phase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas. J clin oncol. 2017 May 20;35(15_suppl):11000.
   Web of Science ®Google Scholar
• Gong J, Yan J, Forscher C, et al. Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas. Drug Des Devel Ther. 2018 Apr 06;12:777–786. PubMed PMID: 29670334; PubMed Central PMCID: PMC5896668.
   PubMed Web of Science ®Google Scholar
• Pourmorteza M, Rahman ZU, Young M. Evofosfamide, a new horizon in the treatment of pancreatic cancer. Anticancer Drugs. 2016 Sep;27(8):723–725. PubMed PMID: 27232101; eng.
   PubMed Web of Science ®Google Scholar
• Duan JX, Jiao H, Kaizerman J, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008 Apr 24;51(8):2412–2420. PubMed PMID: 18257544; eng.
   PubMed Web of Science ®Google Scholar
• Larue RT, Van De Voorde L, Berbee M, et al. A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer. 2016 Aug 17;16:644. PubMed PMID: 27535748; PubMed Central PMCID: PMC4989456. eng.
   PubMed Web of Science ®Google Scholar
• Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017 Aug;18(8):1089–1103. PubMed PMID: 28651927; eng.
   PubMed Web of Science ®Google Scholar
• Moulton RD, Ruterbories KJ, Bedwell DW, et al. In vitro characterization of the bioconversion of pomaglumetad methionil, a novel metabotropic glutamate 2/3 receptor agonist peptide prodrug. Drug Metab Dispos. 2015 May;43(5):756–761. PubMed PMID: 25755052; eng.
   PubMed Web of Science ®Google Scholar
• Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018 Jul;13(4):341–345. PubMed PMID: 29771694; eng.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick DL, Schmidt WK, Morales R, et al. In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD prodrug of oxycodone. J Opioid Manag. 2017 Jan/Feb;13(1):39–49. PubMed PMID: 28345745; eng.
   PubMedGoogle Scholar